These findings highlight the critical role of the FOXA1-BMI1 regulatory axis in the progression of NPC, indicating that the inhibition of BMI1 could offer a promising therapeutic approach for treating NPC, particularly in cases with diminished FOXA1 activity. This evidence concerns the gene BMI1 and nasopharyngeal carcinoma.